Stonegate Updates Coverage on Burcon NutraScience Corporation (BU) 1Q27

Stonegate Capital Partners has continued its coverage of Burcon NutraScience Corporation (TSX: BU) as the plant-based protein company moves deeper into its commercial growth phase. The latest coverage comes as Burcon approaches its fiscal 1Q27 reporting period, with investors increasingly focused on production volumes, customer adoption, revenue growth and the company’s ability to improve operating leverage.

Burcon’s investment story has changed significantly over the past year. The company has moved beyond the construction and commissioning phase of its Galesburg, Illinois production facility and is now focused on increasing utilization. Stonegate’s previous coverage highlighted the transition toward early commercial production, growing customer activity and the potential for higher volumes to improve fixed-cost absorption.

Burcon Enters a New Commercial Phase

Burcon NutraScience specializes in plant-based proteins and has developed proprietary ingredients designed for use in food and beverage applications. Its commercial strategy has increasingly centered on turning its technology and product portfolio into recurring production and sales opportunities.

The Galesburg facility represents a major part of that strategy. During fiscal 2026, Burcon completed commissioning and began commercial production across its Peazazz pea protein, Puratein C canola protein and FavaPro fava protein lines. This marked an important shift from a development-oriented business toward a manufacturing and commercialization model.

For investors, the significance of the transition is that future growth may increasingly depend on throughput and customer demand rather than simply achieving technical milestones. If production volumes continue to rise, the company could potentially spread its fixed operating expenses over a larger revenue base, creating an opportunity for margin improvement.

Revenue Momentum Remains a Key Indicator

Stonegate’s most recent publicly available Burcon coverage before the 1Q27 period showed sequential improvement in revenue. Fiscal 4Q26 revenue reached approximately $0.83 million, compared with about $0.74 million in the preceding quarter. Stonegate also noted that sales were tracking materially higher during the following quarter based on April and May activity.

The sequential increase is important because Burcon is still operating from a relatively small revenue base. At this stage, even modest changes in customer orders can have a meaningful effect on quarterly results. The more important question for 1Q27, however, is whether the company can demonstrate sustained growth rather than a one-quarter increase.

Investors are therefore likely to watch reported revenue alongside production volumes, customer activity and the pace of new commercial programs. Stronger recurring demand would provide greater visibility into future revenue and could help validate the company’s investment in Galesburg.

Customer Pipeline Provides Growth Potential

Another important element of Burcon’s commercial outlook is the breadth of its customer pipeline. Stonegate previously reported that the company had more than 30 purchasing customers and over 200 active projects spanning pea, canola and fava protein applications.

These projects represent potential future opportunities, although an active project does not necessarily translate immediately into meaningful recurring revenue. Food and beverage companies typically require testing, formulation work, customer approvals and production validation before ingredients become part of commercial products.

That makes conversion of development projects into repeat orders one of the most important indicators for Burcon’s next stage. A growing number of customers placing recurring orders would provide stronger evidence that the company’s proteins are moving from trials into broader commercial use.

Pea, Canola and Fava Proteins Diversify the Portfolio

Burcon is also seeking to reduce dependence on a single protein category by commercializing multiple plant-based ingredients. Peazazz targets pea protein applications, while Puratein C addresses canola protein and FavaPro is focused on fava protein.

This broader portfolio could allow Burcon to participate in different formulation opportunities across the food and beverage industry. It also gives customers additional ingredient choices as manufacturers look for proteins with specific nutritional, functional and sensory characteristics.

The commercial success of each product will ultimately depend on customer adoption, pricing, production economics and the ability to manufacture consistently at scale.

Galesburg Utilization Is Central to the Investment Case

The Galesburg facility is increasingly central to the Burcon investment thesis. Stonegate has described the company as moving from commissioning into an early utilization phase, with production volumes beginning to rise. The company also achieved a production record, with daily output reported at roughly 60% above January through March levels in the period discussed in Stonegate’s 4Q26 update.

Higher utilization matters because manufacturing facilities carry significant fixed costs. When production is low, those costs can weigh heavily on margins. As output increases, a larger volume of products can absorb those expenses, potentially improving the economics of each additional unit produced.

For 1Q27, investors may therefore pay close attention to whether Burcon can maintain the improving production cadence. Consistent utilization would strengthen the argument that the company is progressing from startup operations toward a more established commercial manufacturing platform.

Funding Supports the Scale-Up

Burcon’s ability to finance its expansion is another consideration. Stonegate’s latest coverage highlighted approximately $6.9 million of completed funding, with about $3.0 million remaining undrawn and management targeting $10 million in calendar-year 2026 sales.

Access to capital can give the company additional flexibility as customer volumes increase. At the same time, investors will continue to monitor cash usage because Burcon remains in a scale-up period and has not yet reached the earnings profile of a mature manufacturing business.

The balance between investment and revenue growth will be particularly important. If sales increase rapidly enough to absorb a larger portion of operating expenses, the company could gradually reduce its reliance on external financing to support expansion.

What Investors Could Watch in 1Q27

As Burcon moves through fiscal 1Q27, several operating indicators are likely to remain central to the market’s assessment of the company.

• Revenue growth: Investors will want to see whether the recent sequential improvement continues.
• Production volumes: Sustained increases would indicate improving utilization of Galesburg.
• Customer conversions: Movement from development projects to repeat commercial orders could improve revenue visibility.
• Product diversification: Adoption across pea, canola and fava proteins could broaden the company’s revenue base.
• Margins and operating expenses: Higher utilization could help absorb fixed costs and reduce the impact of startup expenses.
• Cash position: Continued liquidity will remain important while Burcon scales production.

Commercial Execution Becomes the Main Test

Burcon’s story is increasingly less about whether it can build and commission a production facility and more about how effectively it can utilize that facility. The company has already established commercial production capabilities across several protein categories. The next challenge is converting those capabilities into a growing and sustainable revenue stream.

Stonegate’s coverage suggests that improving customer volume and utilization could create an opportunity for better fixed-cost absorption. This means that revenue growth may have an increasingly meaningful effect on the company’s operating profile as production expands.

However, the transition is still developing. A growing project pipeline does not guarantee commercial contracts, and higher production does not automatically translate into profitability. Investors will need to evaluate the quality and durability of demand as more quarterly data becomes available.

Burcon’s Outlook Beyond 1Q27

The longer-term opportunity for Burcon rests on the continued adoption of plant-based protein ingredients and the company’s ability to establish itself as a reliable commercial supplier. Its multi-product strategy gives it exposure to several areas of the alternative protein market, while Galesburg provides the infrastructure needed to support larger-scale production.

If customer conversions accelerate and production continues to increase, Burcon could gradually develop a more predictable revenue base. That would represent a significant evolution from its earlier development-stage profile.

Conversely, slower customer adoption, weaker order growth or continued cash requirements could delay the path toward improved profitability. For that reason, the company’s upcoming financial disclosures will be important for determining whether the commercial ramp is progressing in line with expectations.

Conclusion

Stonegate’s continued coverage of Burcon NutraScience highlights a company undergoing a significant commercial transition. The completion of Galesburg commissioning and the launch of production across pea, canola and fava protein products have created the foundation for the next stage of growth.

Heading into fiscal 1Q27, the central issue for investors is execution. Revenue growth, production utilization, customer conversions and cash management will provide important signals about whether Burcon can turn its production platform and customer pipeline into a scalable business.

The company remains in an early stage of commercialization, but the progression from facility commissioning to increasing customer activity gives investors a clearer set of operating milestones to monitor. Continued improvement in these areas could strengthen the case for future growth, while weaker execution would highlight the risks associated with scaling a relatively young manufacturing operation.

Frequently Asked Questions

What is Burcon NutraScience Corporation?

Burcon NutraScience Corporation is a plant-based protein company focused on developing and commercializing protein ingredients for food and beverage applications. Its portfolio includes pea, canola and fava protein products.

What is the importance of Burcon’s Galesburg facility?

The Galesburg facility provides Burcon with commercial-scale production capabilities. The company has moved from commissioning toward greater utilization, making the facility central to its revenue growth strategy.

What products does Burcon produce?

Burcon’s commercial portfolio includes Peazazz pea protein, Puratein C canola protein and FavaPro fava protein.

What should investors watch in 1Q27?

Key areas include quarterly revenue, production volumes, customer orders, conversion of development projects into commercial business, operating expenses, margins and the company’s cash position.

Why is production utilization important for Burcon?

Higher utilization can allow fixed manufacturing costs to be spread across a larger volume of products. If revenue grows faster than the associated fixed expenses, operating leverage could improve.

Does Burcon’s customer pipeline guarantee future revenue?

No. Active projects and customer trials represent potential opportunities, but they must progress through testing, formulation, approval and commercial adoption before they generate meaningful recurring revenue.

What is the main opportunity for Burcon going forward?

The main opportunity is to convert its production capabilities and customer pipeline into sustained commercial sales while increasing utilization at Galesburg. Successful execution could improve revenue visibility and operating leverage over time.

What are the main risks?

Key risks include slower-than-expected customer adoption, inconsistent production volumes, continued cash consumption, manufacturing costs and delays in converting development projects into recurring commercial orders.